Currently, there are no specific<unk>  targeting EV-D68. Although the management of<unk> es in general is only supportive, the development of pharmacologic<unk>  has recently emerged. Immune globulin therapy has demonstrated clinical and laboratory benefit among some patients with<unk>  infection. Antiviral medications against<unk> es, such as pleconaril, are currently being studied for patients with severe infections caused by other subtypes of<unk> es.
Enterovirus 68 future or investigational therapies
Hepatitis D future or investigational therapies
Hepatitis E future or investigational therapies
Hepatitis B future or investigational therapies
Hepatitis C future or investigational therapies
Cytomegalovirus future or investigational therapies
Hepatitis E primary prevention
COVID-19 future or investigational therapies